Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome

Jane E. Whitney, MD, MSCE; Rui Feng, PhD; Natalka Koterba, BS; Fang Chen, PhD; Jenny Bush, RN, BSN; Kathryn Graham, BA; Simon F. Lacey, PhD; Jan Joseph Melenhorst, PhD; Samir M. Parikh, MD; Scott L. Weiss, MD, MSCE; Nadir Yehya, MD, MSCE

Objectives: Acute respiratory distress syndrome occurring in the setting of direct versus indirect lung injury may reflect different pathobiologies amenable to different treatment strategies. We sought to test whether a panel of plasma biomarkers differed between children with sepsis-associated direct versus indirect acute respiratory distress syndrome. We hypothesized that a biomarker profile indicative of endothelial activation would be associated with indirect acute respiratory distress syndrome.

Design: Observational cohort.

Setting: Academic PICU.

Subjects: Patients less than 18 years old with sepsis-associated direct (pneumonia, n = 52) or indirect (extrapulmonary sepsis, n = 46) acute respiratory distress syndrome.

Interventions: None.

Measurements and Main Results: Of 58 biomarkers examined, 33 differed by acute respiratory distress syndrome subtype. We used classification and regression tree methodology to examine associations between clinical and biochemical markers and acute respiratory distress syndrome subtype. The classification and regression tree model using only clinical variables (age, sex, race, oncologic comorbidity, and Pediatric Risk of Mortality-III score) performed worse than the classification and regression tree model using five clinical variables and 58 biomarkers. The best classification and regression tree model used only four endothelial biomarkers, including elevated angiopoietin-2/angiopoietin-1 ratio, vascular cell-adhesion molecule, and von Willebrand factor, to identify indirect acute respiratory distress syndrome. Test characteristics were 89% (80–97%) sensitivity, 80% (69–92%) specificity, positive predictive value 84% (74–93%), and negative predictive value 86% (76–96%).

Conclusions: Indirect lung injury in children with acute respiratory distress syndrome is characterized by a biomarker profile indicative of endothelial activation, excess inflammation, and worse outcomes. A model using four biomarkers has the potential to be useful for more precisely identifying patients with acute respiratory distress syndrome whose pathobiology may respond to endothelial-targeted therapies in future trials.

Key Words: acute respiratory distress syndrome; children; endothelium; lung injury; pediatric; sepsis

Acute respiratory distress syndrome (ARDS) that occurs in the setting of infection can result from indirect (e.g., extrapulmonary sepsis) or direct (i.e., pneumonia) lung injury. Etiology of lung injury is not always considered in trials of ARDS, which may have contributed to negative trials of ARDS therapies. This issue is exacerbated in children, as pediatric ARDS
management is often extrapolated from adults, despite possessing a distinct epidemiology (1). There are a paucity of studies examining the differences in biologic mechanism of pediatric ARDS, and improved understanding of the pathobiology of lung injury may allow an evaluation of differential response to therapies stratified by biologic subtypes.

Studies of adults with ARDS suggest differences in disease pathogenesis of ARDS arising from indirect versus direct lung injury (2), with indirect ARDS characterized by increased activation of the vascular endothelium and direct ARDS is characterized by epithelial injury (2–4). Our prior study suggested a potential role of endothelial activation in indirect ARDS occurring in children with extrapulmonary sepsis; however, this study excluded children with direct ARDS (5). Pneumonia, which reflects direct lung injury, is the most common cause of ARDS in children (1), and it remains unknown how its biomarker profile differs from that of indirect ARDS due to extrapulmonary infection.

Prior reports examining the pathobiologic mechanism of indirect ARDS in children, adults, and animal models have documented altered blood levels of biomarkers involved in regulation of vascular permeability (2, 4–7), neutrophil adhesion and chemotaxis (5, 8), platelet activation (5, 9, 10), and inflammation (3, 11). Prior reports examining the pathobiology of direct ARDS in adults (2) and mice (12) have documented increased circulating markers of lung epithelial injury. Few reports of indirect ARDS and no reports of direct ARDS included children, and the pathobiology of indirect versus direct ARDS has never been directly compared in children. Furthermore, these limited studies have interrogated relatively few biomarkers, thus providing only a partial view of endothelial activation and epithelial injury, and thus may miss an optimal combination of biomarkers to differentiate indirect from direct ARDS, and findings require external validation. Improved understanding of the pathobiology of lung injury in indirect versus direct ARDS could better inform our understanding of expected disease course (13) or response to therapies (14).

Focusing on children with pulmonary and extrapulmonary sepsis, the most common causes of ARDS in children (1), we sought to determine if alterations in a comprehensive panel of plasma biomarkers differed in children with sepsis-associated indirect versus direct ARDS. We hypothesized that alterations in specific biomarkers would differ by ARDS subtype. We further hypothesized that a biomarker profile consistent with endothelial activation would be associated with indirect ARDS.

The parent sepsis study included patients less than 18 years old with severe sepsis or septic shock defined as: 1) greater than or equal to two systemic inflammatory response syndrome criteria, 2) suspected or confirmed systemic infection, and 3) greater than or equal to two organ system dysfunctions or cardiovascular dysfunction (17), and it excluded patients with WBC count less than 0.5 × 10^9/L, known mitochondrial disorder, or unrepaired cyanotic congenital heart disease. The parent ARDS study included intubated patients greater than 1 month and less than 18 years old with ARDS defined by Berlin criteria, which were in use when the first patient was enrolled, including: 1) acute respiratory failure within 7 days of known risk factor requiring mechanical ventilation, 2) \( P_{\text{A}O_2}/F_{\text{I}O_2} \leq 300 \) in two consecutive arterial blood gas samples taken at least 2 hours apart with the patient receiving invasive positive end-expiratory pressure at least 5 cm H~2~O, and 3) bilateral infiltrates on chest x-ray (18), and it excluded patients with chronic invasive mechanical ventilation, respiratory failure from primarily cardiac failure, or unrepaired cyanotic congenital heart disease.

Patients eligible for the current study had blood collected as part of their participation in the parent study, had sufficient volume of residual blood to permit biomarker analysis, and had consented for residual blood to be used for future research. This analysis was limited to patients who met criteria for sepsis (17) within 72 hours of meeting criteria for ARDS (18).

The primary site of infection was determined to be pulmonary (i.e., pneumonia) or extrapulmonary using established criteria (19, 20) with three-person adjudication of cases in which the site of infection was ambiguous after initial review. Patients with "direct ARDS" had infectious pneumonia and patients with "indirect ARDS" had extrapulmonary sepsis.

**Biomarkers**

Blood was collected in an EDTA or lithium heparin tube less than or equal to 72 hours of meeting criteria for ARDS. Samples were centrifuged within 30 minutes of collection at 3,000 x g for 10 minutes and aliquoted plasma was stored at ~80°C. Plasma was thawed once at the time of biomarker measurement, which was performed at the Penn Center for Cellular Immunotherapies.

Biomarker panel components were defined a priori based on prior reports suggesting utility in sepsis, ARDS, or pathways distinguishing these syndromes including inflammatory biomarkers (C-reactive protein, endocan, interleukins, interferons, monocyte chemoattractant protein, monocyte induced by interferon γ, macrophage inflammatory protein-1α/β, serum glycoprotein 130, soluble receptor for advanced glycation end-products [sRAGE], and tumor necrosis factor [TNF]-α/β [4, 21–23]) and endothelial biomarkers, including: angioptietin family biomarkers (Ang-1, Ang-2, Ang-2/-1 ratio, and Tie-2 [5, 6, 24]), cell adhesion molecules (intracellular adhesion molecule, vascular cell-adhesion molecule [VCAM], E-selectin, and endocan [25, 26]), vascular endothelial growth factor (VEGF) family biomarkers (VEGF, soluble fms-like tyrosine kinase, VEGF-R1, VEGF-R2, and VEGF-R3 [5, 27]), prothrombotic (von Willebrand factor [vWF] and thrombomodulin [9, 28]), chemotactic proteins (eotaxin, interferon gamma-induced protein-10, cluster of differentiation [CD]-14, CD-30,

**MATERIALS AND METHODS**

**Study Design and Population**

This study was approved with a waiver of informed consent by the Institutional Review Board at the Children’s Hospital of Philadelphia (CHOP). We conducted a secondary analysis of prospectively collected plasma from a cohort of pediatric patients with ARDS admitted to the PICU of a single academic children’s hospital (CHOP). Participants had been enrolled in one of two prospective observational parent studies of pediatric sepsis (15) and ARDS (4, 16) between May 2014 and January 2018.

Patients eligible for the current study had blood collected as part of their participation in the parent study, had sufficient volume of residual blood to permit biomarker analysis, and had consented for residual blood to be used for future research. This analysis was limited to patients who met criteria for sepsis (17) within 72 hours of meeting criteria for ARDS (18).

The primary site of infection was determined to be pulmonary (i.e., pneumonia) or extrapulmonary using established criteria (19, 20) with three-person adjudication of cases in which the site of infection was ambiguous after initial review. Patients with “direct ARDS” had infectious pneumonia and patients with “indirect ARDS” had extrapulmonary sepsis.
and CD-163 [29]), and growth factors (epidermal growth factor, fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and hepatocyte growth factor [1, 30]). Biomarkers were measured using a combination of commercially available assays (Life Technologies, Carlsbad, CA; EMD Millipore; Darmstadt, Germany), custom multiplex panels (R&D Systems, Minneapolis, MN), and enzyme-linked immunosorbent assay (ELISA) with human-specific reagents. Samples were run in duplicate, and standard curves for each analyte were required to have R² > 95%.

Data Collection
Clinical data including demographics, comorbidities, and primary site of infection were collected using the Research Data Capture system (31) by one investigator (J.E.W.), who reviewed all patient charts and was blinded to biomarker measurements. Oxygenation index (OI [Fio₂ × mean airway pressure]/Pao₂) and Pao₂/Fio₂ were calculated to reflect ARDS severity at the time of biomarker measurement. In the absence of arterial blood gas data, we computed oxygen saturation index (Fio₂ × mean airway pressure/spo₂), and spo₂/Fio₂ ratio then converted these values to OI and Pao₂/Fio₂ ratios (32), using accepted cutoffs (1). Illness severity less than 12 hours of PICU admission was summarized using the Pediatric Risk of Mortality (PRISM)-III score (33).

Outcomes
The main outcomes were biomarker concentrations by ARDS subtypes.

Confounders
Clinical variables were chosen a priori as potential confounders based on biologic plausibility of an association with the exposure or outcome, providing they were absent in the causal pathway linking exposure and outcome (34). We considered five confounders: age, sex, race, oncologic comorbidity, and PRISM-III score.

Statistical Analyses
Analyses were performed using Stata version 14 (StataCorp, College Station, TX) and SAS (SAS Institute, Cary, NC). We reported median and interquartile range for continuous variables and proportions for categorical variables. We compared continuous variables using Wilcoxon rank sum and proportions using chi-squared or Fisher exact test.

First, we determined the association between biomarkers and ARDS subtype (indirect/direct) using univariate logistic regression. When used as predictors, biomarkers were expressed as log-transformed units of standard deviation to facilitate comparison with other arrays. Next, we generated two models to determine the association between clinical or biochemical predictor variables and ARDS subtype using the classification and regression tree (CART [35]). Compared with traditional regression approaches, CART provides flexibility to allow for nonlinear effects and interaction effects of predictors, and it generates optimal cutoffs for continuous predictors (35).

We also performed a supplementary analysis using elastic net (EN) as a comparator method, since it takes into account variable grouping, in order to account for potential biomarker clusters that naturally associated. We used CART rather than EN as the primary analytic method, because we did not know if the relationship between biomarkers and ARDS type would be linear, CART does not require selection of tuning parameters, and the optimal cutoff values required for EN, which represent the probability of ARDS type per patient, are subject to bias.

The first CART model used only the five clinical variables (age, sex, race, oncologic comorbidity, and PRISM-III score) as predictors, and the second model used all 58 biomarkers and the five clinical variables. Each model resulted in a decision tree in which each branchpoint was determined by a predictor variable and a cutoff value, and each end node contains a predictor for the outcome variable. We used five-fold cross-validation to mitigate overfitting. We reported the test characteristics for each decision tree, and the models were compared using a paired likelihood regression method (36).

The EN model used 10-fold cross validation to select optimal tuning parameters α and λ for penalized logistic regression models. We applied EN using the selected α and λ to select a set of predictors from all biomarkers. The final models were refitted using the selected variables. We used individual predicted probabilities to generate the receiver-operating-characteristic curve (ROC) and reported the area under the ROC curve (AUC). We chose a probability cutoff optimized for combined sensitivity and specificity.

RESULTS
Among 332 potentially eligible patients, 98 met all inclusion criteria, including 46 with indirect ARDS and 52 with direct ARDS (Supplemental Fig. 1, http://links.lww.com/CCX/A443). Fifteen cases (15%) required three-person adjudication to determine the primary site of infection. Patient characteristics are shown in Table 1. Patients with direct ARDS had a higher prevalence of pulmonary comorbidity (p = 0.006). PRISM-III score was higher in patients with indirect ARDS (p = 0.007). Fifteen patients (15%) died prior to hospital discharge, including 11 with indirect and four with direct ARDS (p = 0.046).

Individual Biomarkers and ARDS Subtype
Figure 1 shows the unadjusted odds of indirect ARDS for each biomarker. Supplemental Table 1 (http://links.lww.com/CCX/A445) shows biomarker values by ARDS subtype. Thirty-three biomarkers differed by ARDS subtype; 31 were higher in indirect ARDS, whereas Ang-1 and regulated on activation, normal T cell expressed and secreted (RANTES) were higher in direct ARDS.

Biomarker Clusters and ARDS Subtype
In the first CART model (model 1), which used five clinical variables (age, sex, nonwhite/white race, oncologic comorbidity, and PRISM-III) as predictors and ARDS subtype as the outcome, a tree using age and PRISM-III score discriminated indirect from direct ARDS (Supplemental Fig. 2, http://links.lww.com/CCX/A444).

In the second CART model (model 2), which used all biomarkers plus five clinical variables as predictors, elevated Ang-2/Ang-1 ratio, VCAM, and vWF concentration identified indirect ARDS (Fig. 2).

The positive likelihood ratio (LR+) of model 1 was 2.03, the LR+ of model 2 was 4.52, and the ratio of the two was 0.45 (95% CI,
### TABLE 1. Patient Demographics and Clinical Characteristics by Group Are Shown

| Patient Characteristic | Indirect ARDS (n = 46) | Direct ARDS (n = 52) | P* |
|------------------------|------------------------|----------------------|----|
| Age (yr)               | 5.1 (3.6–13.5)         | 5.9 (2.5–13.2)       | 0.83 |
| Sex, n (%)             |                        |                      |    |
| Female                 | 21 (46)                | 23 (44)              | 0.53 |
| Male                   | 25 (54)                | 29 (56)              |    |
| Race                   |                        |                      |    |
| Black/African American | 10 (22)                | 15 (29)              | 0.04 a |
| Other                  | 8 (17)                 | 18 (35)              |    |
| White                  | 28 (61)                | 19 (37)              |    |
| Comorbidities b        |                        |                      |    |
| None                   | 9 (20)                 | 10 (19)              | 0.58 |
| Cardiac                | 9 (20)                 | 10 (19)              | 0.58 |
| Pulmonary              | 10 (22)                | 26 (50)              | 0.006 b |
| Gastrointestinal       | 19 (41)                | 18 (35)              | 0.54 |
| Endocrine              | 7 (15)                 | 10 (19)              | 0.40 |
| Renal                  | 1 (2)                  | 0 (0)                | 0.47 |
| Rheumatologic          | 3 (7)                  | 0 (0)                | 0.10 |
| Immunologic            | 3 (7)                  | 4 (8)                | 0.57 |
| Hematologic            | 4 (9)                  | 2 (4)                | 0.28 |
| Oncologic              | 11 (24)                | 4 (8)                | 0.03 b |
| Musculoskeletal        | 7 (15)                 | 6 (12)               | 0.41 |
| Dermatologic           | 1 (2)                  | 1 (2)                | 0.72 |
| Neurologic             | 18 (39)                | 28 (54)              | 0.11 |
| Immunosuppressed c     | 16 (35)                | 9 (17)               | 0.40 |
| Oxygenation index      | 76 (5.1–11)            | 8 (5.1–13.4)         | 0.52 |
| Pao2/Fio2 ratio        | 241 (166–291)          | 225 (153–291)        | 0.50 |
| Pediatric Risk of Mortality-III score | 15 (10–24) | 9 (6–15) | 0.007 c |

Sepsis source

| Respiratory | 0 (0) | 52 (100) |
| Blood       | 19 (41) | 0 (0) |
| Gastrointestinal | 12 (26) | 0 (0) |
| Urinary     | 5 (11) | 0 (0) |
| CNS         | 1 (2) | 0 (0) |
| Skin        | 2 (4) | 0 (0) |
| Musculoskeletal | 1 (2) | 0 (0) |
| Unknown     | 6 (13) | 0 (0) |

ARDS = acute respiratory distress syndrome.

*p value reflects difference between indirect versus direct ARDS. Significance is defined as *p < 0.05.

*bCategories are not mutually exclusive as some patients had more than one baseline comorbidity.

*cImmunosuppressed patients included those with immune deficiencies and those receiving immunosuppressive therapies.

Data are presented as median (interquartile range) or n (%). Boldface values indicate race, pulmonary and oncologic comorbidity, and Pediatric Risk of Mortality-III score differed by ARDS type.

0.25–0.80, p = 0.007). The negative likelihood ratio (LR–) of model 1 was 0.20, the LR– for model 2 was 0.14, the ratio of the two was 1.42 (95% CI, 0.55–3.70, p = 0.5). Both ratios suggest that model 2 is significantly better for discriminating ARDS subtype than model 1. Diagnostics for both models are presented in Table 2. Compared with model 1, model 2 had similar sensitivity (89% [80–97%] vs 89% [77–78%]), superior specificity (80% [69–92%] vs 57% [41–71%]), positive predictive value (84% [74–93%] vs 70% [57–80%]), and negative predictive value (86% [76–96%] vs 81% [64–93%]).

In the EN model, which used all biomarkers, high Ang-2, interleukin (IL)-8, TNF-R1, and low RANTES identified indirect ARDS. Compared with CART model 2, EN had inferior sensitivity (65% [51–78%] vs 86% [80–97%]), similar specificity (83% [69–92%] vs 80% [69–92%]), positive predictive value (81% [66–91%] vs 84% [74–93%]), and inferior negative predictive value (68% [54–80%] vs 86% [76–96%]). The AUC was 0.84 and the optimal cutoff probability was 68%. Diagnostics are summarized in Supplemental Table 2 (http://links.lww.com/CCX/A446).

### DISCUSSION

In this cohort of children with sepsis-associated ARDS, 33 of 58 biomarkers differed by ARDS subtype, and a biomarker profile indicative of endothelial activation and inflammation was associated with indirect ARDS. Using CART analysis, a model using four endothelial biomarkers discriminated ARDS subtype better than a model using clinical variables. Using EN analysis, a model using four biomarkers (one endothelial and three inflammatory) discriminated ARDS subtype. Elevated Ang-2 was identified by both models to be associated with indirect ARDS. This result supports a role for endothelial activation and inflammation in the pathogenesis of indirect, but not direct, ARDS in children. Discrimination of disease subphenotypes according to pathobiology may permit investigation of therapies most likely to ameliorate sequelae of inflammation or endothelial activation (prognostic enrichment) and may improve identification of patients at risk for worse outcomes (prognostic enrichment).

Elevated Ang-2 identified indirect ARDS by CART and EN. Ang-2 antagonism of the Tie-2 receptor causes weakened endothelial cell junctions, increased expression of leukocyte adhesion molecules (e.g., VCAM), and increased prothrombotic proteins at the endothelial surface (e.g., vWF) (37). Ang-1 promotes vascular quiescence (37), so increased Ang-2/Ang-1 ratio indicates a state of endothelial activation, which has been associated with poor outcomes in patients with sepsis and acute lung injury (5). VCAM promotes migration of leukocytes and endothelial progenitor cells to the source of infection and vascular damage (38). vWF causes platelet aggregation on the vessel wall (39) and is associated with microangiopathy in patients with sepsis (40, 41) and worse clinical outcomes in patients with ARDS (42).

Our finding that increased Ang-2/Ang-1 ratio is associated with indirect ARDS by CART is consistent with prior literature, including our prior finding of increased Ang-2 in patients with ARDS and indirect lung injury (4). Calfe et al (24) previously reported that low Ang-2 was associated with direct ARDS in septic adults.
and Reilly et al (7) used causal inference methods to implicate Ang-2 in the development of ARDS in septic adults. Our finding that increased vWF is associated with indirect ARDS by CART is consistent with prior reports by Rubin (9), who documented high vWF in adults with ARDS secondary to indirect lung injury, and Calfee et al (24), who documented lower vWF in adults with direct compared with indirect ARDS. To our knowledge, VCAM has not previously been studied in sepsis-associated ARDS.

Several biomarkers measured in our cohort, which did not discriminate ARDS subtype, performed differently from those in prior reports. Ware et al (3) found sRAGE, IL-6, and IL-8 to be associated with development of ARDS in adults with sepsis. IL-6 and IL-8 were higher in our patients with indirect compared with direct ARDS (Supplemental Table 1, http://links.lww.com/CCX/A445), and elevated IL-8 was associated with indirect ARDS by EN. IL-6 and IL-8 levels were lower in our cohort than Ware et al’s (3), possibly due to differences in timing of measurements, measurement method (i.e., multiplex versus singleplex ELISA), or pediatric versus adult physiology. Despite being suggested as a marker of alveolar epithelial damage (12), we found no difference in sRAGE between indirect and direct ARDS. However, sRAGE is also expressed in the endothelium and is associated with the strength of the immune response (43).

Supplementary EN analysis identified an association between high TNF-RII, consistent with prior literature showing elevated TNF-RII in adult ARDS (44), and elevated IL-8 was associated with indirect ARDS by EN. IL-6 and IL-8 levels were lower in our cohort than Ware et al’s (3), possibly due to differences in timing of measurements, measurement method (i.e., multiplex versus singleplex ELISA), or pediatric versus adult physiology. Despite being suggested as a marker of alveolar epithelial damage (12), we found no difference in sRAGE between indirect and direct ARDS. However, sRAGE is also expressed in the endothelium and is associated with the strength of the immune response (43).

Supplementary EN analysis identified an association between high TNF-RII, consistent with prior literature showing elevated TNF-RII in adult ARDS (44), and elevated IL-8 was associated with indirect ARDS by EN. IL-6 and IL-8 levels were lower in our cohort than Ware et al’s (3), possibly due to differences in timing of measurements, measurement method (i.e., multiplex versus singleplex ELISA), or pediatric versus adult physiology. Despite being suggested as a marker of alveolar epithelial damage (12), we found no difference in sRAGE between indirect and direct ARDS. However, sRAGE is also expressed in the endothelium and is associated with the strength of the immune response (43).

Supplementary EN analysis identified an association between high TNF-RII, consistent with prior literature showing elevated TNF-RII in adult ARDS (44), and elevated IL-8 was associated with indirect ARDS by EN. IL-6 and IL-8 levels were lower in our cohort than Ware et al’s (3), possibly due to differences in timing of measurements, measurement method (i.e., multiplex versus singleplex ELISA), or pediatric versus adult physiology. Despite being suggested as a marker of alveolar epithelial damage (12), we found no difference in sRAGE between indirect and direct ARDS. However, sRAGE is also expressed in the endothelium and is associated with the strength of the immune response (43).
with indirect, but not direct, ARDS suggests differences in under-
biomarkers indicative of endothelial activation and inflamma-
ty, and positive and negative predictive values. The association of
markers identified indirect ARDS with good sensitivity, specific-
ARDS. Models incorporating endothelial and inflammatory bio-
thalial activation and inflammation were associated with indirect
ARDS group. Finally, although our selection of biomarkers was
alyzed by prior literature, it was not exhaustive, and endo-
thalial biomarkers were overrepresented. Results from CART
alysis were supported but completely replicated by supple-
mentary EN analysis. Future studies are needed to validate pro-
spectively our findings.

Our study also has several strengths. This was the first study to
use plasma biomarkers to compare indirect and direct ARDS in
pediatric patients. We used a large panel of biomarkers, assembled
based on previous adult, pediatric, and animal studies, to exam-
pathobiologic differences in pediatric ARDS subphenotypes.
The model of four biomarkers that identified indirect ARDS
demonstrated both biologic plausibility and good discriminative
performance.

CONCLUSIONS
In a cohort of pediatric ARDS, biomarkers indicative of endo-
thalial activation and inflammation were associated with indirect
ARDS. Models incorporating endothelial and inflammatory bio-
markers identified indirect ARDS with good sensitivity, specific-
ity, and positive and negative predictive values. The association of
biomarkers indicative of endothelial activation and inflammation
with indirect, but not direct, ARDS suggests differences in under-
lying pathobiology. External validation is required. Prospective
studies are warranted to investigate further biological differences
in ARDS subtypes. Plasma biomarkers, as a tool for predictive
enrichment, may aid in identification of patients with ARDS
whose physiology may respond more favorably to targeted thera-
pies in future studies.

TABLE 2. Diagnostic Characteristics of Two Classification and Regression Analysis Models

| Model | Indirect ARDS (n = 46) | Direct ARDS (n = 52) | Sensitivity % (95% CI) | Specificity % (95% CI) | Positive Predictive Value % (95% CI) | Negative Predictive Value % (95% CI) |
|-------|------------------------|---------------------|-----------------------|----------------------|-------------------------------------|-------------------------------------|
| Model 1 (clinical variables) |            |                     | 89 (77–96)          | 57 (41–71)          | 70 (57–80)                           | 81 (64–93)                           |
| Predicted indirect | 26 | 6 | | | | |
| Predicted direct | 20 | 46 | | | | |
| Model 2 (biomarkers and clinical variables) | 89 (80–97) | 80 (69–92) | 84 (74–93) | 86 (76–96) | | |
| Predicted indirect | 37 | 6 | | | | |
| Predicted direct | 9 | 46 | | | | |

ARDS = acute respiratory distress syndrome.

This study was performed at the Children’s Hospital of Philadelphia.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s website (http://journals.lww.com/ccxjournal).

Supported, in part, by the National Institutes of Health: National Heart, Lung,
and Blood Institute (NHLBI) T32 HL008891 (to Dr. Whitney trainee), Loan
Repayment Program 2674-1 (to Dr. Whitney), National Institute of Child
Health and Human Development K12HD047349 (to Dr. Weiss), National
Institute of General Medical Sciences K23GM110496 (to Dr. Weiss), NHLBI
K23HL138688 (to Dr. Yehya), and the Department of Anesthesiology & Criti-
cal Care at the Children’s Hospital of Philadelphia.

The authors have disclosed that they do not have any potential conflicts of
interest.

For information regarding this article, E-mail: jane.whitney@childrens.harvard.edu

REFERENCES
1. Khemani RG, Smith L, Lopez-Fernandez YM, et al; Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE) Investigators; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Paediatric acute respiratory distress syndrome incidence and epi-
demiology (PARDIE): An international, observational study. Lancet Respir
Med 2019; 7:115–128
2. Calfee CS, Janz DR, Bernard GR, et al: Distinct molecular phenotypes of
direct vs indirect ARDS in single-center and multicenter studies. Chest
2015; 147:1539–1548
3. Ware LB, Koyama T, Zhao Z, et al: Biomarkers of lung epithelial injury
and inflammation distinguish severe sepsis patients with acute respira-
tory distress syndrome. Crit Care 2013; 17:R253
4. Yehya N, Thomas NJ, Meyer NJ, et al: Circulating markers of endothe-
rial and alveolar epithelial dysfunction are associated with mortality in
pediatric acute respiratory distress syndrome. Intensive Care Med 2016;
42:1137–1145
5. Whitney JE, Zhang B, Koterba N, et al: Systemic endothelial activation
is associated with early acute respiratory distress syndrome in children
with extrapulmonary sepsis. Crit Care Med 2020; 48:334–352
6. Parikh SM, Mammo T, Schultz A, et al: Excess circulating angiopoietin-
2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med
2006; 3:e46
7. Reilly JP, Wang F, Jones TK, et al: Plasma angiopoietin-2 as a potential causal
marker in sepsis-associated ARDS development: Evidence from Mendelian
randomization and mediation analysis. Intensive Care Med 2018; 44:1849–1858
8. Calfee CS, Ware LB, Glidden DV, et al; National Heart, Blood, and Lung
Institute Acute Respiratory Distress Syndrome Network: Use of risk
reclassification with multiple biomarkers improves mortality prediction
in acute lung injury. Crit Care Med 2011; 39:711–717
9. Rubin DB, Wiener-Kronish JP, Murray JP, et al: Elevated von Willebrand
factor antigen is an early plasma predictor of acute lung injury in nonpul-
monary sepsis syndrome. J Clin Invest 1990; 86:474–480
10. Ware LB, Eisner MD, Thompson BT, et al: Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. *Am J Respir Crit Care Med* 2004; 170:766–772
11. Yehya N, Thomas NJ, Wong HR: Evidence of endotypes in pediatric acute hypoxemic respiratory failure caused by sepsis. *Pediatr Crit Care Med* 2019; 20:110–112
12. Jabaudon M, Blondonnet R, Roszyk L, et al: Soluble receptor for advanced glycation end-products predicts impaired alveolar fluid clearance in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2015; 192:191–199
13. Prescott HC, Calfee CS, Thompson BT, et al: Toward smarter lumping and smarter splitting: Rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. *Am J Respir Crit Care Med* 2016; 194:147–155
14. Iwashyna TJ, Burke JF, Sussman JB, et al: Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. *Am J Respir Crit Care Med* 2015; 192:1045–1051
15. Weiss SL, Zhang D, Bush J, et al: Persistent mitochondrial dysfunction linked to prolonged organ dysfunction in pediatric sepsis. *Crit Care Med* 2019; 47:1433–1441
16. Yehya N, Thomas NJ, Margulies SS: Circulating nucleosomes are associated with mortality in pediatric acute respiratory distress syndrome. *Am J Physiol Cell Mol Physiol* 2016; 42:1137–1145
17. Goldstein B, Giroir B, Randolph A: International Consensus Conference on Pediatric Sepsis: International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med* 2005; 6:2–8
18. Ranieri VM, Rubenfeld GD, Thompson BT, et al: Acute respiratory distress syndrome: The Berlin definition. *JAMA* 2012; 307:2526–2533
19. Horan TC, Andrus M, Dudek MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008; 36:309–332
20. Yehya N, Keim G, Thomas NJ: Subtypes of pediatric acute respiratory distress syndrome have different predictors of mortality. *Intensive Care Med* 2018; 44:1230–1239
21. Jones TK, Feng R, Kerchberger VE, et al: Plasma sRAGE acts as a genetically regulated causal intermediate in sepsis-associated acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020; 201:47–56
22. Li YT, Wang YC, Lee HL, et al: Monocyte chemoattractant protein-1, a possible biomarker of multiorgan failure and mortality in ventilator-associated pneumonia. *Int J Mol Sci* 2019; 20:2218
23. Matera G, Puccio R, Giancotti A, et al: Impact of interleukin-10, soluble CD25 and interferon-y on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: A prospective observational study. *Crit Care* 2013; 17:R64
24. Calfee CS, Gallagher D, Abbott J, et al: NHLBI ARDS Network: Plasma angiopoietin-2 in clinical acute lung injury: Prognostic and pathogenetic significance. *Crit Care Med* 2012; 40:1731–1737
25. Orbegozo D, Rahmania L, Irazabal M, et al: Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome. *Ann Intensive Care* 2017; 7:93
26. Whalen MJ, Doughty LA, Carlos TM, et al: Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure. *Crit Care Med* 2000; 28:2600–2607
27. Whitney JE, Silverman M, Norton JS, et al: Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor as novel biomarkers for poor outcomes in children with severe sepsis and septic shock. *Pediatr Emerg Care* 2018; 001:–5
28. Orwell BE, Spicer AC, Zinter MS, et al: Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): A prospective observational cohort study. *Crit Care* 2015; 19:435
29. Punyadeera C, Schneider EM, Schaffer D, et al: A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. *J Emerg Trauma Shock* 2010; 3:26–35
30. Faiotto VB, Franci D, Enz Hubert RM, et al: Circulating levels of the angiogenesis mediators endoglin, HB-EGF, BMP-9 and FGF-2 in patients with severe sepsis and septic shock. *J Crit Care* 2017; 42:162–167
31. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; 42:377–381
32. Khemani RG, Patel NR, Bart RD 3rd, et al: Comparison of the pulse oximetric saturation/fraction of inspired oxygen ratio and the PaO2/fraction of inspired oxygen ratio in children. *Chest* 2009; 135:662–668
33. Pollack MM, Patel KM, Ruttimann UE: PRISM III: An updated pediatric risk of mortality score. *Crit Care Med* 1996; 24:743–752
34. Lederer DJ, Bell SC, Branson RD, et al: Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals. *Ann Am Thorac Soc* 2019; 16:22–28
35. Breiman L, Friedman J, Olsen R, et al: Classification and Regression Trees. Belmont, CA, Wadsworth, 1984
36. Gu W, Pepe MS: Estimating the capacity for improvement in risk prediction with a marker. *Biostatistics* 2009; 10:172–186
37. Sack KD, Kellum IA, Parikh SM: The angiopoietin-Tie2 pathway in critical illness. *Crit Care Clin* 2020; 36:201–216
38. Rafat N, Tönshoff B, Bierhaus A, et al: Endothelial progenitor cells in regeneration after acute lung injury: Do they play a role? *Am J Respir Cell Mol Biol* 2013; 48:399–405
39. Methia N, André P, Denis CV, et al: Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. *Blood* 2001; 98:1424–1428
40. Clauss RA, Bockmeyer CL, Soosdorf M, et al: The balance between von-Willebrand factor and its cleaving protease ADAMTS13: Biomarker in systemic inflammation and development of organ failure? *Curr Mol Med* 2010; 10:236–248
41. Clauss RA, Bockmeyer CL, Budde U, et al: Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. *Thorbm Haemost* 2009; 101:239–247
42. Zinter MS, Delucchi KL, Kong MY, et al: Early plasma matrix metalloproteinase profiles. A novel pathway in pediatric acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2019; 199:181–189
43. Schmidt AM, Yan SD, Yan SF, et al: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. *J Clin Invest* 2001; 108:949–955
44. Parsons PE, Matthy MA, Ware LB, et al; National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network: Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2005; 288:1426–1431
45. Sinha P, Ware LB: Selective tumour necrosis factor receptor-1 inhibition in acute lung injury: A new hope or a false dawn? *Thorax* 2018; 73:699–701
46. Chen CH, Chen YL, Sung PH, et al: Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets. *Oncotarget* 2017; 8:82415–82429